crinetics team

About

Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. We have assembled a seasoned team with extensive expertise in drug discovery and development in endocrine G-protein coupled receptors (GPCRs) and built a highly productive drug discovery organization.

We have discovered a pipeline of oral nonpeptide (small molecule) new chemical entities that target peptide GPCRs to treat a variety of rare endocrine diseases where treatment options have significant efficacy, safety and/or tolerability limitations.

Our lead product candidate, CRN00808, is currently undergoing two Phase 2 clinical trials for the treatment of acromegaly and our second oral product development candidate, CRN01941, has entered the clinic for the treatment of neuroendocrine tumors. We are also developing oral nonpeptide therapeutics for hyperinsulinism and Cushing’s disease.

Our vision is to build the leading endocrine company which consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives.


  1. CRN01941
    Phase 1 begins

    CRN01941 Phase 1 begins


  2. Gina Ford

    Gina Ford joined as VP, Corporate Strategy and Commercial Planning


  3. ACROBAT EVOLVE
    and EDGE Begin

    ACROBAT EVOLVE and EDGE Begin


  4. IPO

    Completed $117 million IPO on NASDAQ


  5. Alan Krasner

    Alan Krasner joined as CMO


  6. Phase 1
    Results

    Reported initial results from Phase 1 study of CRN00808


  7. Series B

    Completed $63.5 million Series B financing


  8. Marc Wilson

    Marc Wilson joined as CFO


  9. Phase 1
    Study

    Initiated Phase 1 Study of CRN00808 for acromegaly


  10. $2.4m Grant

    Awarded $2.4 million in SBIR grants for discovery of small molecule therapies targeting Cushing’s disease and hyperinsulinemic hypoglycemia


  11. $2.8m Grant

    Awarded $2.8 million SBIR Phase IIb grant for development of small molecule therapy for acromegaly


  12. Ajay Madan

    Appointed Ajay Madan as VP, Development


  13. Series A

    Completed $40.0 million Series A financing


  14. $1.5m Grant

    Awarded $1.5 million Phase II SBIR grant for discovery of kisspeptin antagonists for women’s health


  15. $2.2m Grant

    Awarded $2.2 million Phase II SBIR grant for discovery and development of a small molecule therapy for acromegaly


  16. FAF Grant
    Awarded

    Awarded first of two grants from Michaelson Prize and Grant Program to investigate veterinary reproductive health


  17. First Lab

    First Crinetics laboratory opened


  18. Phase 1 Grant

    Awarded Phase I SBIR grant to study GPCR biosensors


  19. Incorporated

    Crinetics is incorporated